Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

e potential utility of such partnerships in connection with NeurogesX' non-NGX-4010 development efforts; the potential markets for NeurogesX' product candidates; expected benefits of NeurogesX' product candidates; and the suitability of NGX-1998 for certain treatments and potential usage by broader physician populations. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may be limited to certain indications; maintaining or obtaining adequate cash and other resources to carry on operations through potential regulatory approval of NGX-4010 and to carry out activities to commercialize NGX-4010, if approved; difficulties or delays in NeurogesX entering into commercialization partnerships for NGX-4010; physician or patient reluctance to use NGX-4010 or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Operations

'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/20/2014)... NJ (PRWEB) August 20, 2014 WriteResult®, ... announced today that it has expanded its myPROpad™ ePRO ... the EQ-5D-5L, one of the most widely used ... measuring general health status. The EQ-5D is used during ... generate a measure that can be used to demonstrate ...
(Date:8/20/2014)... Sofia, Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the ... rates and connectors for Lucene, SOLR and Elasticsearch. ... change for this high performance triplestore – GraphDB™ ... organizations interested in deploying the only mature enterprise ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... and Company 29th Annual Health Care Conference on Tuesday, ... parties may access a live webcast of the presentation ... is recommended that listeners log on 15 minutes early ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting ... on Tuesday, March 17, 2009 at 8:00 a.m. ... Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ... will be webcast, and a recording will be made available ...
... Research Centers in Germany and Portugal Indicates ... Wash., March 10 BioLife Solutions, Inc. ... and marketer of proprietary cGMP hypothermic storage ... and organs, today announced that an independent ...
Cached Biology Technology:Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM) 2Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM) 3Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM) 4
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... To improve students, chances of completing introductory biology ... Houston (UH) implemented a comprehensive student success program, ... failure. , Through a grant from the ... of Biology and Biochemistry embarked on a pilot ... for non-majors and "Introductory Biology" for science majors. ...
(Date:8/19/2014)... be used in supermarkets to encourage healthier spending habits? ... answer that very question by tracking the purchasing records ... System to rate the nutritional value of foods for ... Lab,s David Just, PhD, and Brian Wansink PhD, author ... of over 150 Hannaford Supermarkets in the Northeastern United ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... sedatives have been the gold standard for treating newborns ... opiates themselves are superior to sedatives for treating infants ... pregnant. , Opiates appear to better "ameliorate the withdrawal, ... according to two new systematic reviews done by David ...
... For years, sedatives have been the gold standard for ... suggests that opiates themselves are superior to sedatives for ... methadone while pregnant. , Opiates appear to better "ameliorate ... of seizures," according to two new systematic reviews done ...
... Vast genetic resources ?"blue gold" on the international ... exploitation, warns a new report from the Japan-based ... , Increasingly recognized as important to humankind for ... resources are now more accessible and vulnerable than ...
Cached Biology News:Researchers discover new route to hemoglobin synthesis 2Opiates Better Than Sedatives For Treating Newborns In Withdrawal 2Clear rules needed to govern deep sea bioprospecting: UNU 2Clear rules needed to govern deep sea bioprospecting: UNU 3Clear rules needed to govern deep sea bioprospecting: UNU 4Clear rules needed to govern deep sea bioprospecting: UNU 5
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
Biology Products: